| Zacks Company Profile for Madrigal Pharmaceuticals, Inc. (MDGL : NSDQ) |
|
|
| |
| • Company Description |
| Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
Number of Employees: 915 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $544.51 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 284,111 shares |
| Shares Outstanding: 23.06 (millions) |
| Market Capitalization: $12,554.04 (millions) |
| Beta: -1.05 |
| 52 Week High: $615.00 |
| 52 Week Low: $286.44 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
6.21% |
5.38% |
| 12 Week |
5.99% |
3.39% |
| Year To Date |
-6.50% |
-13.64% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
William J. Sibold - President and Chief Executive Officer; Director
Julian C. Baker - Chair of the Board
Mardi C. Dier - Executive Vice President and Chief Financial Offic
Rita Thakkar - Senior Vice President and Chief Accounting Officer
Rebecca Taub - Director
|
|
Peer Information
Madrigal Pharmaceuticals, Inc. (GSAC)
Madrigal Pharmaceuticals, Inc. (CASIF)
Madrigal Pharmaceuticals, Inc. (ALCD.)
Madrigal Pharmaceuticals, Inc. (OMNN)
Madrigal Pharmaceuticals, Inc. (CGPI.)
Madrigal Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 558868105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 07/30/26
|
|
Share - Related Items
Shares Outstanding: 23.06
Most Recent Split Date: 7.00 (0.03:1)
Beta: -1.05
Market Capitalization: $12,554.04 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-1.27 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-7.45 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 8.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 53.85% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/30/26 |
|
|
|
| |
